New versus Old Oral Anticoagulants: How can we set the Scale needle? Considerations on a Case Report

Arcadi, FA; Portaro, S; Giorgianni, R; Naro, A; Casella, C; Genovese, C; Marino, S; Calabrò, RS

doi:10.3390/medicina55030071

CINECA IRIS Institutional Research Information System

IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.

Ischemic stroke is a complex multifactorial disorder. Anticoagulation is a growing research area, with the main goal of preventing systemic embolization and stroke. We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. We therefore suggest a closer monitoring of the safety and efficacy of dabigatran. Moreover, in the presence of multifactorial causes of pro-coagulation, we believe that warfarin should remain the mainstay of oral anticoagulation

Titolo:	New versus Old Oral Anticoagulants: How can we set the Scale needle? Considerations on a Case Report
Autori:	Arcadi FA PORTARO, SIMONA Giorgianni R NARO, ANTONINO CASELLA, Carmela Genovese C Marino S CALABRO', ROCCO SALVATORE (Corresponding) mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2019
Rivista:	MEDICINA
Abstract:	Ischemic stroke is a complex multifactorial disorder. Anticoagulation is a growing research area, with the main goal of preventing systemic embolization and stroke. We report the case of a 41-year-old woman with antiphospholipid syndrome who was unsuccessfully treated with Dabigatran, a new oral anticoagulant, as she developed a major stroke involving the right carotid artery, due to deep venous thrombosis with pulmonary embolism. We therefore suggest a closer monitoring of the safety and efficacy of dabigatran. Moreover, in the presence of multifactorial causes of pro-coagulation, we believe that warfarin should remain the mainstay of oral anticoagulation
Handle:	http://hdl.handle.net/11570/3140234
Appare nelle tipologie:	14.a.1 Articolo su rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11570/3140234

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.